Publications by authors named "G P Bonmarchand"
In acquired thrombotic thrombocytopenic purpura (TTP), the persistence of severe ADAMTS13 deficiency (<10%) during remission is associated with more relapse. Preemptive (ie, after remission) administration of rituximab in these patients to prevent relapses remains controversial. We performed a cross-sectional analysis of 12-year follow-up data to compare the relapse incidence with or without preemptive rituximab infusion.
View Article and Find Full Text PDFArticle Synopsis
- Infectious events are significant triggers for thrombotic thrombocytopenic purpura (TTP), with a study finding that 41% of TTP patients showed signs of infection at diagnosis.
- The majority of identified infectious agents were Gram-negative bacilli, and infected patients had more frequent fever, but infections did not affect long-term outcomes.
- Genetic analysis revealed specific polymorphisms in the TLR-9 gene are more common in TTP patients, indicating they may increase susceptibility to the condition.
Background: Acquired thrombotic thrombocytopenic purpura is still associated with a 10-20% death rate. It has still not been possible to clearly identify early prognostic factors of death. This study involved thrombotic thrombocytopenic purpura patients with acquired severe (<10% of normal activity) ADAMTS13 deficiency and aimed to identify prognostic factors associated with 30-day death.
View Article and Find Full Text PDFRationale: The use of noninvasive ventilation (NIV) as an early weaning/extubation technique from mechanical ventilation remains controversial.
Objectives: To investigate NIV effectiveness as an early weaning/extubation technique in difficult-to-wean patients with chronic hypercapnic respiratory failure (CHRF).
Methods: In 13 intensive care units, 208 patients with CHRF intubated for acute respiratory failure (ARF) who failed a first spontaneous breathing trial were randomly assigned to three groups: conventional invasive weaning group (n = 69), extubation followed by standard oxygen therapy (n = 70), or NIV (n = 69).